Roche withdraws drug for a type of breast cancer in United States –

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann
Aug 27 (Reuters) – Roche Holding AG (ROG.S) has decided to withdraw its immunotherapy Tecentriq as a treatment for a type of breast cancer in the United States, the drugmaker said on Thursday following a consultation with the Food and Drug Administration.
The drug received accelerated approval in 2019 to treat inoperable, locally advanced or metastatic triple-negative breast cancer in people whose tumors express PD-L1, a protein that may help the cancer avoid detection by the immune system.
But it failed last year to deliver positive follow-up data required by the regulator.
In April, an FDA panel that reviewed cancer drugs that are granted accelerated approval but have failed to show clinical benefit in confirmatory trials, however, voted in favor of keeping Tecentriq in the market.
Since then Bristol Myers Squibb (BMY.N), Merck (MRK.N) and AstraZeneca (AZN.L) have pulled out their treatments for other types of cancers due to a lack of benefit seen in confirmatory trials.
Roche said on Friday that due to the recent changes in the treatment landscape, the FDA no longer considers it appropriate to maintain the accelerated approval.
The decision does not affect the use of Tecentriq for other approved indications in the United States and was not related to any changes in either the efficacy or safety associated with the drug, the company said.
Earlier this year, Roche had withdrawn the drug from use in treating bladder cancer in the United States. Outside the country, it will continue to be available for the breast cancer indication. read more
Tecentriq is also approved to treat non-small cell lung cancer, small cell lung cancer and liver cancer and brought in sales of 2.7 billion Swiss francs ($2.96 billion) in 2020.
($1 = 0.9116 Swiss francs)
Our Standards: The Thomson Reuters Trust Principles.
Sign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
Subscribe to our newsletter to get all the news you need to start your day.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved


Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart